Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned an average recommendation of “Hold” from the nine brokerages that are currently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $26.67.

A number of research firms recently weighed in on LMAT. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a research note on Friday, April 28th. Canaccord Genuity reiterated a “buy” rating and issued a $28.00 price target on shares of LeMaitre Vascular in a report on Thursday, April 27th. Craig Hallum initiated coverage on shares of LeMaitre Vascular in a report on Tuesday, June 6th. They issued a “hold” rating and a $31.00 price target on the stock. Stifel Nicolaus lifted their price target on shares of LeMaitre Vascular from $25.00 to $29.00 and gave the company a “buy” rating in a report on Friday, April 28th. Finally, Benchmark Co. downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Monday, July 10th. They noted that the move was a valuation call.

LeMaitre Vascular (NASDAQ:LMAT) traded down 1.49% on Tuesday, hitting $29.14. 159,233 shares of the stock traded hands. The stock has a market cap of $548.09 million, a price-to-earnings ratio of 48.65 and a beta of 0.63. The company’s 50 day moving average price is $30.02 and its 200-day moving average price is $25.94. LeMaitre Vascular has a 52-week low of $13.81 and a 52-week high of $33.22.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, May 4th. The medical instruments supplier reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.03. LeMaitre Vascular had a net margin of 12.52% and a return on equity of 13.36%. The company had revenue of $24.10 million for the quarter, compared to analysts’ expectations of $23.48 million. The company’s revenue for the quarter was up 18.7% on a year-over-year basis. On average, analysts forecast that LeMaitre Vascular will post $0.70 earnings per share for the current fiscal year.

In other news, VP Michael T. Wijas sold 2,346 shares of the business’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $31.42, for a total value of $73,711.32. Following the sale, the vice president now directly owns 3,584 shares in the company, valued at approximately $112,609.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David B. Roberts sold 44,340 shares of the business’s stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $31.14, for a total transaction of $1,380,747.60. Following the completion of the sale, the insider now owns 46,945 shares in the company, valued at $1,461,867.30. The disclosure for this sale can be found here. Over the last quarter, insiders sold 317,805 shares of company stock worth $9,910,332. 23.70% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of LMAT. Bank of America Corp DE increased its stake in LeMaitre Vascular by 0.3% in the first quarter. Bank of America Corp DE now owns 193,651 shares of the medical instruments supplier’s stock worth $4,770,000 after buying an additional 536 shares during the period. American International Group Inc. increased its stake in LeMaitre Vascular by 7.0% in the first quarter. American International Group Inc. now owns 8,310 shares of the medical instruments supplier’s stock worth $205,000 after buying an additional 545 shares during the period. Blair William & Co. IL increased its stake in LeMaitre Vascular by 6.9% in the first quarter. Blair William & Co. IL now owns 11,977 shares of the medical instruments supplier’s stock worth $295,000 after buying an additional 768 shares during the period. Bank of New York Mellon Corp increased its stake in LeMaitre Vascular by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 88,552 shares of the medical instruments supplier’s stock worth $2,181,000 after buying an additional 1,408 shares during the period. Finally, Prudential Financial Inc. increased its stake in LeMaitre Vascular by 2.1% in the first quarter. Prudential Financial Inc. now owns 97,350 shares of the medical instruments supplier’s stock worth $2,398,000 after buying an additional 2,040 shares during the period. Hedge funds and other institutional investors own 66.35% of the company’s stock.

WARNING: “LeMaitre Vascular, Inc. (LMAT) Given Consensus Rating of “Hold” by Analysts” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/18/lemaitre-vascular-inc-lmat-given-consensus-rating-of-hold-by-analysts.html.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.